Review: taking Risperidone and Intuniv together


Summary

Drug interactions are reported among people who take Risperidone and Intuniv together. This review analyzes the effectiveness and drug interactions between Risperidone and Intuniv. It is created by eHealthMe based on reports of 344 people who take the same drugs from FDA and social media, and is updated regularly.

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Risperidone

Risperidone has active ingredients of risperidone. It is often used in schizophrenia. (latest outcomes from Risperidone 23,150 users)

Intuniv

Intuniv has active ingredients of guanfacine hydrochloride. It is often used in attention deficit hyperactivity disorder. (latest outcomes from Intuniv 1,613 users)

On Sep, 14, 2016

344 people who take Risperidone, Intuniv are studied.


Number of reports submitted per year:

Risperidone and Intuniv drug interactions.

Drug effectiveness over time:

Risperidone:
  • < 1 month: 0.0% - (0 of 2 people)
  • 1 - 6 months: 0.0% - (0 of 2 people)
  • 6 - 12 months: 50.0% - (2 of 4 people)
  • 1 - 2 years: 20.0% - (1 of 5 people)
  • 2 - 5 years: 27.0% - (3 of 11 people)
  • 5 - 10 years: 75.0% - (3 of 4 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)
Intuniv:
  • < 1 month: 33.0% - (1 of 3 people)
  • 1 - 6 months: 25.0% - (1 of 4 people)
  • 6 - 12 months: 0.0% - (0 of 3 people)
  • 1 - 2 years: 0.0% - (0 of 7 people)
  • 2 - 5 years: 12.0% - (1 of 8 people)
  • 5 - 10 years: 100.0% - (1 of 1 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)

Drug effectiveness by gender:

Risperidone:
  • female: 20.0% - (1 of 5 people)
  • male: 34.0% - (8 of 23 people)
Intuniv:
  • female: 20.0% - (1 of 5 people)
  • male: 14.0% - (3 of 21 people)

Drug effectiveness by age:

Risperidone:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 16.0% - (2 of 12 people)
  • 10-19: 35.0% - (5 of 14 people)
  • 20-29: 100.0% - (1 of 1 people)
  • 30-39: 0.0% - (0 of 0 people)
  • 40-49: 100.0% - (1 of 1 people)
  • 50-59: 0.0% - (0 of 0 people)
  • 60+: 0.0% - (0 of 0 people)
Intuniv:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 7.0% - (1 of 13 people)
  • 10-19: 18.0% - (2 of 11 people)
  • 20-29: 100.0% - (1 of 1 people)
  • 30-39: 0.0% - (0 of 0 people)
  • 40-49: 0.0% - (0 of 1 people)
  • 50-59: 0.0% - (0 of 0 people)
  • 60+: 0.0% - (0 of 0 people)

Most common drug interactions over time *:

< 1 month:
  • accidental exposure
  • malaise
  • physical assault
  • convulsion
  • excessive eye blinking
  • eye pain
  • muscle spasms
  • muscle twitching
  • drug ineffective
  • abnormal weight gain
1 - 6 months:
  • gynaecomastia
  • emotional disorder
  • weight increased
  • tic
  • homicidal ideation
  • tremor
  • hallucination, visual
  • aggression
  • aggression aggravated
  • convulsion
6 - 12 months:
  • aggression
  • emotional disorder
  • gynaecomastia
  • agitation
  • tardive dyskinesia
  • weight increased
  • convulsion
  • extrapyramidal disorder
  • foaming at mouth
  • anticonvulsant drug level below therapeutic
1 - 2 years:
  • gynaecomastia
  • weight increased
  • emotional disorder
  • emotional distress
  • obesity
  • tic
  • suicidal ideation
  • abnormal weight gain
  • aggression
  • blood prolactin increased
2 - 5 years:
  • gynaecomastia
  • emotional distress
  • obesity
  • blood triglycerides increased
  • glucose tolerance impaired
  • emotional disorder
  • weight increased
  • acne
  • breast pain
  • breast tenderness
5 - 10 years:
  • blood prolactin decreased
  • pain
  • mental disorder
  • tardive dyskinesia
  • extrapyramidal disorder
  • movement disorder
  • gynaecomastia
  • weight increased
  • emotional distress
  • arthralgia
10+ years:
  • gynaecomastia
  • obesity
  • emotional distress
  • immobile
  • joint stiffness
  • emotional disorder
not specified:
  • aggression
  • gynaecomastia
  • weight increased
  • abnormal behaviour
  • drug ineffective
  • somnolence
  • agitation
  • emotional distress
  • bradycardia
  • hypotension

Most common drug interactions by gender *:

female:
  • aggression
  • abnormal behaviour
  • weight increased
  • drug ineffective
  • musculoskeletal pain
  • convulsion
  • somnolence
  • intentional self-injury
  • irritability
  • muscular weakness
male:
  • gynaecomastia
  • weight increased
  • emotional distress
  • aggression
  • obesity
  • emotional disorder
  • drug ineffective
  • abnormal behaviour
  • agitation
  • tic

Most common drug interactions by age *:

0-1:
  • aggression
  • convulsion
  • agitation
  • depressed level of consciousness
  • fatigue
  • foaming at mouth
  • pancreatitis acute
  • somnolence
  • tardive dyskinesia
  • weight gain
2-9:
  • accidental overdose
  • hypotension
  • drug ineffective
  • fatigue
  • convulsion
  • weight increased
  • somnolence
  • aggression
  • eye pain
  • hyperhidrosis
10-19:
  • aggression
  • abnormal behaviour
  • tic
  • weight increased
  • agitation
  • gynaecomastia
  • drug ineffective
  • somnolence
  • vomiting
  • convulsion
20-29:
  • grand mal convulsion
  • aggression
  • agitation
  • agonal rhythm
  • blood glucose increased
  • blood pressure increased
  • bradycardia
  • constipation
  • cough
  • decreased activity
30-39:
  • blood cholesterol increased
  • borderline personality disorder
  • convulsion
  • diabetes mellitus
  • diabetes mellitus inadequate control
  • epilepsy
  • feeling abnormal
  • glucose tolerance impaired
  • headache
  • hyperlipidaemia
40-49:
  • visual impairment
  • atrophy
  • burning sensation
  • claustrophobia
  • constipation
  • convulsion
  • crying
  • depression
  • drug ineffective
  • enuresis
50-59:
  • abdominal distension
  • arthralgia
  • bronchitis
  • chronic obstructive pulmonary disease
  • diabetes mellitus inadequate control
  • diarrhoea
  • folliculitis
  • gallbladder disorder
  • hepatic enzyme increased
  • hypertension
60+:
  • cardiac failure congestive
  • back injury
  • cerebrovascular disorder
  • chronic obstructive pulmonary disease
  • concomitant disease progression
  • convulsion
  • drug level decreased
  • ear infection
  • hypoglycaemia
  • hyponatraemia

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Risperidone and Intuniv?

Can you answer these questions?

More questions for: Risperidone, Intuniv

You may be interested in these reviews

More reviews for: Risperidone, Intuniv

On eHealthMe, Risperidone (risperidone) is often used to treat schizophrenia. Intuniv (guanfacine hydrochloride) is often used to treat attention deficit hyperactivity disorder. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.